| GTO ID | GTC2753 |
| Trial ID | NCT05001373 |
| Disease | HIV Infection |
| Therapy | mRNA vaccine |
| Treatment | Core-g28v2 60mer mRNA Vaccine|eOD-GT8 60mer mRNA Vaccine |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health |
| Year | 2021 |
| Country | United States |
| Company sponsor | International AIDS Vaccine Initiative |
| Other ID(s) | IAVI G002 |
| Vector information | |||
|
|||
| Cohort1: eOD-GT8 60mer | |||||||||
|
|||||||||
| Cohort2: Core-g28v2 60mer_eOD-GT8 60mer | |||||||||
|
|||||||||
| Cohort3: Core-g28v2 60mer | |||||||||
|
|||||||||